BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 3970557)

  • 1. [Effect of human recombinant beta-interferon on natural killer activity of peripheral lymphocytes in cancer patients].
    Beika T; Tanaka N; Yamada J; Hizuta A; Onishi K; Akura Y; Hirose K; Orita K
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):362-5. PubMed ID: 3970557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of human recombinant-gamma interferon on the immune function of peripheral blood lymphocytes in cancer patients].
    Yamada J; Tanaka N; Kamitani S; Goto K; Gangi J; Orita K
    Gan To Kagaku Ryoho; 1986 May; 13(5):1946-52. PubMed ID: 2939802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
    Okabe M; Gomi K; Morimoto M; Nakamizo N
    Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell activity depression in peripheral blood and ascites from gastric cancer patients with high TGF-beta 1 expression.
    Yoon SJ; Heo DS; Kang SH; Lee KH; Kim WS; Kim GP; Lee JA; Lee KS; Bang YJ; Kim NK
    Anticancer Res; 1998; 18(3A):1591-6. PubMed ID: 9673375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution of lymphocyte subpopulation and natural killer activity in gastric cancer tissue, normal stomach and various tissues of gastric cancer patients].
    Moritani Y
    Nihon Geka Gakkai Zasshi; 1984 Feb; 85(2):132-42. PubMed ID: 6611484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
    Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
    Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
    Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
    Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-enhancing effect of recombinant human interferon-beta produced in Escherichia coli on human peripheral blood mononuclear cells in vitro.
    Okabe M; Morimoto M; Nakamizo N
    Gan; 1983 Oct; 74(5):743-50. PubMed ID: 6357933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
    Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
    Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
    J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Natural killer (NK) activity of the peripheral blood lymphocytes in cancer patients].
    Song Y
    Zhonghua Wai Ke Za Zhi; 1989 Jun; 27(6):357-8, 381-2. PubMed ID: 2479505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of CDDP administration on NK activity of human peripheral lymphocytes and its modification by corticosteroid as anti-emetic agent].
    Takahashi K; Saijo N; Seki S; Kimata M; Sasaki Y; Shimizu E; Eguchi K; Shinkai T; Tominaga K; Hoshi A
    Gan To Kagaku Ryoho; 1984 Mar; 11(3):492-6. PubMed ID: 6538405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I-II study of recombinant interleukin-2].
    Sano T; Saijo N; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Sakurai M; Takahashi H; Nakano H; Nakagawa K
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):903-13. PubMed ID: 3494427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Local administration of recombinant interferon-beta to patients with cancer-associated body cavity fluids].
    Tanaka N; Terasawa A; Matsui T; Yamada J; Hizuta A; Ichikawa J; Nakayama F; Matsuda T; Orita K
    Gan To Kagaku Ryoho; 1988 Feb; 15(2):237-41. PubMed ID: 3341785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of low doses of alpha interferon in patients with breast cancer.
    Laszlo J; Hood L; Cox E; Goodwin B
    J Biol Response Mod; 1986 Jun; 5(3):206-10. PubMed ID: 3723137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Wolf AM; Wolf D; Steurer M; Gastl G; Gunsilius E; Grubeck-Loebenstein B
    Clin Cancer Res; 2003 Feb; 9(2):606-12. PubMed ID: 12576425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
    Koren HS; Brandt CP; Tso CY; Laszlo J
    J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.